^
    3ms
    A SHR0302 BA Study on Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    ivarmacitinib (SHR0302)
    3ms
    SHR0302 and Steroid as First Line Therapy for Chronic GVHD (clinicaltrials.gov)
    P1, N=73, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Jul 2023 --> Jul 2024
    Trial primary completion date
    |
    prednisone • ivarmacitinib (SHR0302)
    4ms
    A SHR0302 BA Study on Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1 trial
    |
    ivarmacitinib (SHR0302)
    5ms
    To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability (clinicaltrials.gov)
    P1, N=16, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    ivarmacitinib (SHR0302)
    6ms
    A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P3, N=566, Completed, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Jan 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    ivarmacitinib (SHR0302)
    7ms
    A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial (ASH 2023)
    In summary, SHR0302 in combination with prednisone had a good safety and could achieve a high response for naïve-treatment cGVHD, which suggests that SHR0302 combination might become an optimal choice for naïve-treatment cGVHD.
    Clinical • P1 data
    |
    prednisone • ivarmacitinib (SHR0302)
    11ms
    Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Henan Cancer Hospital
    New P1 trial
    |
    ivarmacitinib (SHR0302)
    1year
    A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata. (PubMed, J Am Acad Dermatol)
    Treatment with ivarmacitinib 4 mg and 8 mg doses in moderate and severe AA patients for 24 weeks was efficacious and generally tolerated.
    Clinical • P2 data • Journal
    |
    CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1)
    |
    ivarmacitinib (SHR0302)